Denitza Blagev

Denitza Blagev, MD

Languages spoken: English

Academic Information

Departments Primary - Internal Medicine

Divisions: Public Health

Board Certification

  • American Board of Internal Medicine (Sub: Critical Care Medicine)
  • American Board of Internal Medicine (Sub: Pulmonary Disease)

Education History

Certification Stanford University Graduate School of Business
 Certificate
Health Management Academy
 Certification
Certification University of Utah David Eccles School of Business, Intermountain Health
 Certification
Institute for Health Care Delivery Research, Intermountain Healthcare
Research Fellow University of California, San Francisco
 Research Fellow
University of California, San Francisco
 Clinical Fellow
Internship/Residency University of California, San Francisco
 Intern/Resident
Harvard Medical School
 Clinical Fellow
Internship/Residency Beth Israel-Deaconess Medical Center
 Intern/Resident
New York University, New York
 MD
Undergraduate Yale University
 BS

Selected Publications

Journal Article

  1. Blagev DP, Callahan SJ, Harris D, Collingridge DS, Hopkins RO, Eve JR, Waddoups L, Aston V, Brown S, Lanspa MJ (2023). Prospectively Assessed Long-Term Outcomes of Patients with E-Cigarette- or Vaping-associated Lung Injury. Ann Am Thorac Soc, 19(11), 1892-1899. (Read full article)
  2. Blagev DP, Lanspa MJ (2020). Autopsy insights from the EVALI epidemic. Lancet Respir Med, 8(12), 1165-1166. (Read full article)
  3. Hegewald MJ, Horne BD, Trudo F, Kreindler JL, Chung Y, Rea S, Blagev DP (2020). Blood Eosinophil Count and Hospital Readmission in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis, 15, 2629-2641. (Read full article)
  4. Stemmer A, Shadmi R, Bregman-Amitai O, Chettrit D, Blagev D, Orlovsky M, Deutsch L, Elnekave E (2020). Using machine learning algorithms to review computed tomography scans and assess risk for cardiovascular disease: Retrospective analysis from the National Lung Screening Trial (NLST). PLoS One, 15(8), e0236021. (Read full article)
  5. Blagev DP, Collingridge DS, Rea S, Carey KA, Mularski RA, Zeng S, Arjomandi M, Press VG (2019). Laboratory-based Intermountain Validated Exacerbation (LIVE) Score stability in patients with chronic obstructive pulmonary disease. BMJ Open Respir Res, 7(1). (Read full article)
  6. Blagev DP, Harris D, Dunn AC, Guidry DW, Grissom CK, Lanspa MJ (2019). Clinical presentation, treatment, and short-term outcomes of lung injury associated with e-cigarettes or vaping: a prospective observational cohort study. Lancet, 394(10214), 2073-2083. (Read full article)
  7. Horne BD, Joy EA, Hofmann MG, Gesteland PH, Cannon JB, Lefler JS, Blagev DP, Korgenski EK, Torosyan N, Hansen GI, Kartchner D, Pope CA 3rd (2018). Short-Term Elevation of Fine Particulate Matter Air Pollution and Acute Lower Respiratory Infection. Am J Respir Crit Care Med, 198(6), 759-766.
  8. Horne BD, Joy EA, Hofmann MG, Gesteland PH, Cannon JB, Lefler JS, Blagev DP, Korgenski EK, Torosyan N, Hansen GI, Kartchner D, Pope CA 3rd (2018). Short-Term Elevation of Fine Particulate Matter Air Pollution and Acute Lower Respiratory Infection. Am J Respir Crit Care Med, 198(6), 759-766. (Read full article)
  9. Blagev DP, Collingridge DS, Rea S, Press VG, Churpek MM, Carey K, Mularski RA, Zeng S, Arjomandi M (2018). Stability of Frequency of Severe Chronic Obstructive Pulmonary Disease Exacerbations and Health Care Utilization in Clinical Populations. COPD, 5(3), 208-220.
  10. Blagev DP, Collingridge DS, Rea S, Press VG, Churpek MM, Carey K, Mularski RA, Zeng S, Arjomandi M (2018). Stability of Frequency of Severe Chronic Obstructive Pulmonary Disease Exacerbations and Health Care Utilization in Clinical Populations. Chronic Obstr Pulm Dis, 5(3), 208-220. (Read full article)
  11. Blagev DP, Collingridge DS, Rea S, Horne BD, Press VG, Churpek MM, Carey KA, Mularski RA, Zeng S, Arjomandi M (2018). The Laboratory-Based Intermountain Validated Exacerbation (LIVE) Score Identifies Chronic Obstructive Pulmonary Disease Patients at High Mortality Risk. Front Med (Lausanne), 5, 173. (Read full article)
  12. Linares-Perdomo O, Hegewald M, Collingridge DS, Blagev D, Jensen RL, Hankinson J, Morris AH (2016). Comparison of NHANES III and ERS/GLI 12 for airway obstruction classification and severity. Eur Respir J, 48(1), 133-41. (Read full article)

Review

  1. Aberegg SK, Maddock SD, Blagev DP, Callahan SJ (2020). Diagnosis of EVALI: General Approach and the Role of Bronchoscopy. [Review]. Chest, 158(2), 820-827. (Read full article)

Editorial

  1. Blagev DP (2022). Comparison Among Different Inhalers in COPD: The Differences Are Too Big and Too Small, and It Matters. Chest, 163(4), 731-732. (Read full article)
  2. Callahan SJ, Lanspa MJ, Blagev DP (2021). Is COVID-19 masking the ongoing youth vaping crisis? Expert Rev Respir Med, 15(9), 1089-1091. (Read full article)
  3. Press VG, Gershon AS, Sciurba FC, Blagev DP (2020). Concerns About Coronavirus Disease-Related Collateral Damage for Patients With COPD. Chest, 158(3), 866-868. (Read full article)
  4. Blagev DP (2020). Better with Time: Reductions in Mortality in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc, 17(6), 684-685. (Read full article)
  5. Blagev DP (2020). No man is an island: e-cigarette, or vaping, associated lung injury in Europe. Eur Respir J, 55(2). (Read full article)
  6. Blagev D (2015). Evaluation of pulmonary complaints in the emergency department. Time to go back to the basics. Ann Am Thorac Soc, 12(5), 625-6. (Read full article)

Letter

  1. Lanspa MJ, Blagev DP, Callahan SJ (2021). Use of e-Cigarettes for Smoking Cessation. [Letter to the editor]. JAMA, 325(10), 1006. (Read full article)
  2. Callahan SJ, Harris D, Collingridge DS, Guidry DW, Dean NC, Lanspa MJ, Blagev DP (2020). Diagnosing EVALI in the Time of COVID-19. [Letter to the editor]. Chest, 158(5), 2034-2037. (Read full article)